News for GenSight Biologics S.A. (0RIM.L)

GenSight Biologics Announces Publication of 5-Year Outcomes for Patients Treated Unilaterally with LUMEVOQ ® Gene Therapy

GenSight Biologics Announces Submission of LUMEVOQ ® Dossier to ANSM to Prepare for Restart of Early Access Program in France

GenSight Biologics Announces Publication of Meta-Analyses Showing Better Outcomes for ND4-LHON Patients Treated with LUMEVOQ ®

GenSight Biologics S.A. reports lower revenues in the first half of 2024, with EPS at -€0.26.

GenSight Biologics Reports Cash Position as of June 30, 2024, and Provides Business Update

GenSight Biologics Launches Newsletter for Retail Investors

GenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates

GenSight Biologics to Present at Upcoming Medical Conferences and Stakeholder Meetings

GenSight Biologics Appoints William Monteith to its Board of Directors

Press Release Gensight Biologics announces the approval of all resolutions supported by the Board of Directors at its Combined General Meeting ...